{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:31Z","timestamp":1760189671710},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is a rare lymphoma with 1000 to 1500 new patients diagnosed per year in the United States. Patients with WM can experience prolonged survival times, which seem to have increased in the last decade, but relapse is inevitable. The identification of recurrent mutations in the MYD88 and CXCR4 genes has opened avenues of research to better understand and treat patients with WM. These developments are giving way to personalized treatment approaches for these patients, focusing on increasing depth and duration of response alongside lower toxicity rates. In the present document, we review the diagnostic differential, the clinical manifestations, and the pathological and genomic features of patients with WM. We also discuss the safety and efficacy data of alkylating agents, proteasome inhibitors, monoclonal antibodies, and Bruton tyrosine kinase inhibitors in patients with WM. Finally, we propose a genomically driven algorithm for the treatment of WM. The future of therapies for WM appears bright and hopeful, but we should be mindful of the cost-effectiveness and long-term toxicity of novel agents.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.365","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"365-370","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Toward personalized treatment in Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"2017","author":[{"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111704025377600_B1","first-page":"194","article-title":"Lymphoplasmacytic lymphoma","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"8","key":"2019111704025377600_B2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstr\u00f6m macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005","volume":"53","author":"Sekhar","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2019111704025377600_B3","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstr\u00f6m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111704025377600_B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111704025377600_B5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111704025377600_B6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111704025377600_B7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111704025377600_B8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"2019111704025377600_B9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/sonc.2003.50074","article-title":"Immunophenotypic analysis of Waldenstrom\u2019s macroglobulinemia","volume":"30","author":"San Miguel","year":"2003","journal-title":"Semin Oncol"},{"issue":"8","key":"2019111704025377600_B10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ajh.24753","article-title":"IgM myeloma: a multicenter retrospective study of 134 patients","volume":"92","author":"Castillo","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111704025377600_B11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m macroglobulinaemia: a task force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111704025377600_B12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstr\u00f6m-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel","volume":"176","author":"D\u2019Sa","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111704025377600_B13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.14743","article-title":"Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"177","author":"Gustine","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111704025377600_B14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.13883","article-title":"Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study","volume":"172","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"key":"2019111704025377600_B15","article-title":"MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr\u00f6m macroglobulinaemia [published online ahead of print 17 October 2016]","author":"Gustine","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111704025377600_B16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.14279","article-title":"Renal disease related to Waldenstr\u00f6m macroglobulinaemia: incidence, pathology and clinical outcomes","volume":"175","author":"Vos","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111704025377600_B17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","article-title":"Bing-Neel syndrome, a rare complication of Waldenstr\u00f6m macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"100","author":"Simon","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"2019111704025377600_B18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111704025377600_B19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/R01VXG46MFCDVNHL","article-title":"Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia. Clinicopathologic features of 12 cases","volume":"120","author":"Lin","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2019111704025377600_B20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"2019111704025377600_B21","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111704025377600_B22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111704025377600_B23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"27","author":"Jim\u00e9nez","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2019111704025377600_B24","doi-asserted-by":"crossref","first-page":"e80088","DOI":"10.1371\/journal.pone.0080088","article-title":"L265P mutation of the MYD88 gene is frequent in Waldenstr\u00f6m\u2019s macroglobulinemia and its absence in myeloma","volume":"8","author":"Mori","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"2019111704025377600_B25","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111704025377600_B26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111704025377600_B27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, signaling, and treatment of Waldenstr\u00f6m macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111704025377600_B28","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111704025377600_B29","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"2019111704025377600_B30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"22","key":"2019111704025377600_B31","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V128.22.2969.2969","article-title":"Lower doses of bendamustine are not associated with lower response rates in previously untreated patients with Waldenstr\u00f6m macroglobulinemia [abstract]","volume":"128","author":"Castillo","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2019111704025377600_B32","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111704025377600_B33","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"23","key":"2019111704025377600_B34","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111704025377600_B35","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111704025377600_B36","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111704025377600_B37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"2019111704025377600_B38","unstructured":"FDA News Release. FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm432123.htm. Accessed 24 May 2017."},{"key":"2019111704025377600_B39","unstructured":"NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines\u00ae). Waldenstr\u00f6m\u2019s macroglobulinemia \/ lymphoplasmacytic lymphoma. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/waldenstroms.pdf. Accessed 24 May 2017."},{"issue":"2","key":"2019111704025377600_B40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111704025377600_B41","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111704025377600_B42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111704025377600_B43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"issue":"16","key":"2019111704025377600_B44","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2019111704025377600_B45","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","article-title":"Rituximab and subcutaneous 2-chloro-2\u2032-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study","volume":"28","author":"Laszlo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111704025377600_B46","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","article-title":"Thalidomide and rituximab in Waldenstrom macroglobulinemia","volume":"112","author":"Treon","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111704025377600_B47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.24175","article-title":"Lenalidomide is safe and active in Waldenstr\u00f6m macroglobulinemia","volume":"90","author":"Fouquet","year":"2015","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111704025377600_B48","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704025377600_B49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.23620","article-title":"Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia","volume":"89","author":"Ghobrial","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111704025377600_B50","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-16-1918","article-title":"Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09-214)","volume":"23","author":"Treon","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111704025377600_B51","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/bjh.13794","article-title":"Rituximab intolerance in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"174","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"key":"2019111704025377600_B52","author":"Furman","year":"2011"},{"issue":"4","key":"2019111704025377600_B53","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/10428194.2016.1222380","article-title":"Idelalisib in Waldenstr\u00f6m macroglobulinemia: high incidence of hepatotoxicity","volume":"58","author":"Castillo","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2019111704025377600_B54","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: atrial of the ECOG-ACRIN Cancer Research Group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"2019111704025377600_B55","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9759","key":"2019111704025377600_B56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"2019111704025377600_B57","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111704025377600_B58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"issue":"33","key":"2019111704025377600_B59","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111704025377600_B60","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111704025377600_B61","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111704025377600_B62","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1182\/blood.V128.22.2956.2956","article-title":"Ixazomib, dexamethasone and rituximab in previously untreated patients with Waldenstr\u00f6m macroglobulinemia [abstract]","volume":"128","author":"Castillo","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111704025377600_B63","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V124.21.1715.1715","article-title":"Updated results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with Waldenstr\u00f6m macroglobulinemia (WM) [abstract]","volume":"124","author":"Siegel","year":"2014","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/365\/1251205\/hem00051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/365\/1251205\/hem00051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:03:12Z","timestamp":1573981392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/365\/21219\/Toward-personalized-treatment-in-Waldenstr%C3%B6m"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.365","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}